Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis.

Item

http://www.wikidata.org/entity/Q38087694

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Clinical pharmacology of tocil ...... juvenile idiopathic arthritis.

@en

type

Item

label

Clinical pharmacology of tocil ...... juvenile idiopathic arthritis.

@en

prefLabel

Clinical pharmacology of tocil ...... juvenile idiopathic arthritis.

@en

P1476

Clinical pharmacology of tocil ...... juvenile idiopathic arthritis.

@en

P2093

Kimio Terao

http://www.w3.org/2001/XMLSchema#string

Peter N Morcos

http://www.w3.org/2001/XMLSchema#string

Tomohisa Saito

http://www.w3.org/2001/XMLSchema#string

Xiaoping Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Differential regulation of neutrophil-activating chemokines by IL-6 and its soluble receptor isoforms

Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolong

Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.

Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis.

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.

The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis.

Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis.

Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome.

The IL-6/sIL-6R complex as a novel target for therapeutic approaches.

P304

123-137

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ECP.13.1

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23473591

http://www.w3.org/2001/XMLSchema#string

P921

Farmakologi

juvenile rheumatoid arthritis